Forty Seven
Advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD7.6b (Public information from Mar 2020)
Menlo Park California (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 |
|---|---|---|---|
| R&D budget | 31.0m | 50.0m | 75.0m |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$75.0m | Series A | ||
$75.0m | Series B | ||
| N/A | €112m Valuation: €479m | IPO | |
* | $4.9b Valuation: $4.9b | Acquisition | |
| Total Funding | AUD232m | ||
Related Content
Recent News about Forty Seven
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.